Navigation Links
SPCG-4 trial: Update on watchful waiting versus radical prostatectomy
Date:3/20/2009

Stockholm, 20 March - In 2005, the Scandinavian Prostate Cancer Group Study 4 (SPCG-4) reported that radical prostatectomy improved prostate cancer survival compared with watchful waiting after a median of 8.2 years of follow-up. At the 24th Annual EAU Congress in Stockholm, Sweden the results after 3 more years of follow-up were reported by Professor Lars Holmberg from Uppsala, Sweden.

The SPCG-4 trial which predominantly included men whose prostate cancer was not detected by PSA screening - was the first randomized trial to show that radical prostatectomy reduces the risk of prostate cancer mortality and the risk of developing metastases.

Lars Holmberg: "Key questions following our previous analyses of this trial, which were based on a median of 8.2 years of follow-up, include whether the absolute and relative benefits of surgical treatment would increase during longer follow-up, as we hypothesized; whether overall mortality would remain reduced; whether the benefit is larger among younger than among older patients; and whether histopathologic parameters can predict lethal outcome following surgery. We think the answer may well be affirmative".

The conclusion of the study is that radical prostatectomy reduces prostate cancer mortality and risk of metastases with little or no further increase in benefit 10 or more years after surgery.

Lars Holmberg: "One of the most striking results of this study was the fact that, in a follow-up of side effects, symptoms and quality of life within the randomised study, the symptom profile was different in the two randomisation groups but the overall rating of quality of life was similar. This may mean that the side effects of radical prostatectomy wear off, people get used to it perhaps." This indicates that well structured pre-treatment information, understanding of the patient's preferences and support during follow-up are central to the management of prostate cancer.

"Radical pros
'/>"/>

Contact: lindy brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. UNC trial: oral contraceptives may ease suffering of women with severe PMS
2. Pressure BioSciences, Inc. Provides Corporate Update
3. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
4. NCCN Presents Updates to NCCN Guidelines for Thyroid Carcinoma
5. Early Detection Remains Key in Updated NCCN Guidelines for Ovarian Cancer
6. New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkins Lymphomas
7. NCCN Announces Updates to Pancreatic Adenocarcinoma Guidelines
8. BullMarket.com Updates Outlook on Biotech Stocks
9. Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update
10. Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
11. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
(Date:4/22/2014)... 22, 2014) The International Communication Association will ... Seattle, Washington. The theme of the 2014 conference ... a networked and digital society. , Featuring over ... over 2,200 Communication scholars representing over 40 countries, ... communication conference in the world. This year,s conference ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... tools, but ,talking, computer program helped , , FRIDAY, ... the written questions American doctors have them answer ... question the usefulness of these screening tools, new ... year at the 2008 Clinical Congress of the ...
... WASHINGTON, Oct. 17 After a destructive,hurricane season that ... the American Public Health Association (APHA) wants to ensure,that ... storms and any other,potential emergencies you may face. With ... a new campaign aimed at encouraging Americans to,make sure ...
... AUBURN HILLS, Mich., Oct. 17 Chrysler LLC ... companies will bring an,innovative diabetes program to its ... developed with the Henry Ford Health System,and is ... and,care with existing workplace wellness initiatives. All employees ...
... into tobacco dependence published online today (Friday 17 October 2008) ... that recent ex-smokers who find exposure to other people,s cigarette ... those who find it unpleasant. , Led by Dr Hayden ... Unit at Barts and The London School of Medicine and ...
... ShotsTM Brings Public Health Message to Austin,s American,Heart ... Heart disease was the leading,cause of death ... in every,10 deaths. People with heart disease are ... complications from the flu. Therefore, the,U.S. Centers for ...
... break fundraising records for breast ... cancer research, SEATTLE, ... Breast Cancer Awareness month to raise money for breast,cancer research. This is ... to help breast cancer research and who has,not completed their will to ...
Cached Medicine News:Health News:Doctors Often Overestimate Patients' Health Literacy 2Health News:Check Your Emergency Preparedness Kits When You Set Your Clocks, Says American Public Health Association Campaign 2Health News:Chrysler LLC Launches Workplace Diabetes Education Program 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 3Health News:How Can Doing Your Will Online Help Cure Breast Cancer? 2
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... SGP ), a leader in hepatitis research, ... III studies of boceprevir, its,investigational oral hepatitis C ... virus (HCV) genotype 1. One study,will be in ... patients,who failed prior treatment (relapsers and nonresponders), an ...
... Laboratories, L.C., a,privately-owned biopharmaceutical company, today announced the ... to evaluate the safety and,efficacy of nitazoxanide in ... with chronic hepatitis C genotype 1 who have ... therapy (peginterferon and,ribavirin). The company expects to announce ...
Cached Medicine Technology:Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 2Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 3Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 4Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 5Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 6Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 7Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 8Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 9Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 10Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3
... Massive hemorrhage associated with displaced pelvic fractures ... faced by orthopaedic and trauma surgeons. , ... antishock garment, external fixation, and internal fixation ... Stabilizer has been developed as a method ...
The large External Fixator consists of rods, clamps, and pins. It has multiple external fixation frames, independent pin placement, and MR safe clamps. The modular frame construction permits fracture...
The DFS Standard Fixator advantages include a highly adjustable system, modular compression/distraction, versatile central body component that provides 360 of rotation, and a positive locking mechani...
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: